TWO RECENT EVENTS have focused the attention of the medical community on the metabolic syndrome: (1) the inclusion of the syndrome in the recently published Adult Treatment Panel III (ATPIII) guidelines of the National Cholesterol Education Program,1 and (2) the creation of an International Classification of Diseases, Ninth Revision diagnostic code, 277.7, which makes reimbursement for treating the syndrome possible. This syndrome, also called dysmetabolic syndrome, syndrome X, and the insulin resistance syndrome, has been the subject of numerous scientific studies. Now momentum is growing to translate knowledge gained from these basic and clinical research studies into day-to-day clinical practice.
Hill JO, Bessesen D. What to Do About the Metabolic Syndrome?. Arch Intern Med. 2003;163(4):395–397. doi:10.1001/archinte.163.4.395